Precision BioSciences to Report Third Quarter Results on November 4, 2024

DTIL 10.29.2024

Full Press ReleaseSEC FilingsOur DTIL Tweets

About Gravity Analytica

Recent News

  • 01.09.2025 - Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
  • 12.18.2024 - Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
  • 11.25.2024 - JonesTrading Virtual Genetic Medicine Day

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.22.2025 - 144 Report of proposed sale of securities
  • 01.08.2025 - 8-K Current report
PDF Version

DURHAM, N.C.--(BUSINESS WIRE)--Oct. 29, 2024--Precision BioSciences, Inc.(Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update onNovember 4, 2024.

AboutPrecision BioSciences, Inc.

Precision BioSciences, Inc.is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information aboutPrecision BioSciences, please visitwww.precisionbiosciences.com.

The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241029759701/en/

Investor and Media Contact:Naresh TannaVice President of Investor Relationsnaresh.tanna@precisionbiosciences.com

Source:Precision BioSciences, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com